Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Harrow, Inc. stock logo
HROW
Harrow
$31.23
-1.7%
$31.66
$20.85
$59.23
$1.17B0.41442,110 shs530,570 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$26.11
-1.5%
$26.70
$16.16
$31.80
$1.07B0.8303,453 shs356,504 shs
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$54.09
-0.2%
$47.05
$26.70
$91.83
$1.10B2.62443,884 shs637,762 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$39.01
+3.5%
$38.84
$6.76
$130.00
$287.00M1.71.36 million shs1.27 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Harrow, Inc. stock logo
HROW
Harrow
-1.67%-13.71%+2.16%+20.91%+21.14%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.47%-10.52%-6.55%+34.03%+38.29%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-0.24%-8.66%+16.77%+34.42%-6.27%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
+3.53%-21.54%+10.92%+95.05%-21.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Harrow, Inc. stock logo
HROW
Harrow
2.5108 of 5 stars
3.51.00.00.03.02.50.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
4.1204 of 5 stars
0.95.02.51.13.43.32.5
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.5506 of 5 stars
4.41.00.00.02.61.70.0
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
3.4116 of 5 stars
3.53.00.00.03.83.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Harrow, Inc. stock logo
HROW
Harrow
3.00
Buy$63.83104.40% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-6.55% Downside
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.78
Moderate Buy$94.1173.99% Upside
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
3.00
Buy$70.0079.44% Upside

Current Analyst Ratings Breakdown

Latest TNXP, HROW, PRAX, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
7/18/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$105.00
7/11/2025
Harrow, Inc. stock logo
HROW
Harrow
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$76.00
7/8/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$97.00 ➝ $115.00
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
6/12/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$62.00
6/12/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/10/2025
Harrow, Inc. stock logo
HROW
Harrow
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Harrow, Inc. stock logo
HROW
Harrow
$199.61M5.74$0.13 per share232.26$1.95 per share16.02
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.04$2.08 per share12.54$6.34 per share4.12
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$8.55M128.87N/AN/A$23.90 per share2.26
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$10.04M28.58N/AN/A$31.82 per share1.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.56N/A78.08N/A-10.19%-25.01%-4.27%8/11/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7833.4712.430.442.68%30.51%6.89%8/27/2025 (Estimated)
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)

Latest TNXP, HROW, PRAX, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52N/AN/AN/A$362.24 millionN/A
8/15/2025Q1 2025
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$6.71N/AN/AN/A$2.60 millionN/A
8/12/2025Q2 2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$3.40N/AN/AN/A$0.16 millionN/A
8/11/2025Q2 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.01N/AN/AN/A$64.23 millionN/A
5/12/2025Q1 2025
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million
5/8/2025Q1 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/2/2025Q1 2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.84%N/A61.54%N/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/AN/AN/AN/AN/A

Latest TNXP, HROW, PRAX, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.71%9/3/20259/3/20259/24/2025
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Harrow, Inc. stock logo
HROW
Harrow
2.01
0.91
0.85
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/A
8.44
8.44
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/A
12.31
11.64

Institutional Ownership

CompanyInstitutional Ownership
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
67.84%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
82.26%

Insider Ownership

CompanyInsider Ownership
Harrow, Inc. stock logo
HROW
Harrow
15.16%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.70%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
0.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Harrow, Inc. stock logo
HROW
Harrow
18036.69 million31.12 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
11020.37 million19.82 millionOptionable
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
507.36 million7.36 millionNot Optionable

Recent News About These Companies

What is Zacks Small Cap's Estimate for TNXP Q2 Earnings?
Zacks Small Cap Has Bullish Forecast for TNXP Q2 Earnings
Tonix Pharma Plans Sales Force for TNX-102 SL
Tonix Pharma Publishes Phase 3 Trial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Harrow stock logo

Harrow NASDAQ:HROW

$31.23 -0.53 (-1.67%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$31.85 +0.62 (+1.99%)
As of 08/1/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$26.11 -0.39 (-1.47%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$26.12 +0.02 (+0.06%)
As of 08/1/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Praxis Precision Medicines stock logo

Praxis Precision Medicines NASDAQ:PRAX

$54.09 -0.13 (-0.24%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$51.76 -2.33 (-4.31%)
As of 08/1/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Tonix Pharmaceuticals stock logo

Tonix Pharmaceuticals NASDAQ:TNXP

$39.01 +1.33 (+3.53%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$40.10 +1.09 (+2.79%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.